Abstract
Drug resistance in malaria and in tuberculosis (TB) are major global health problems. Although the terms multidrug-resistant TB and extensively drug-resistant TB are precisely defined, the term multidrug resistance is often loosely used when discussing malaria. Recent declines in the clinical effectiveness of antimalarial drugs, including artemisinin-based combination therapy, have prompted the need to revise the definitions of and/or to recategorize antimalarial drug resistance to include extensively drug-resistant malaria. Applying precise case definitions to different levels of drug resistance in malaria and TB is useful for individual patient care and for public health.
Highlights
Medscape, LLC is pleased to provide online continuing medical education (CME) for this journal article, allowing clinicians the opportunity to earn CME credit
Recent changes in clinical effectiveness of antimalarial drugs, in particular the emergence of artemisinin resistance, are forcing malaria experts to consider revising the definitions of drug resistance for Plasmodium falciparum
Multidrug resistance of P. falciparum is strictly defined as resistance to >2 antimalarial compounds of different chemical classes, recommended by the National Malaria Control Program (NMCP) [10]
Summary
LLC is pleased to provide online continuing medical education (CME) for this journal article, allowing clinicians the opportunity to earn CME credit. Drug resistance in malaria and TB is useful for individual patient care and for public health. Recent changes in clinical effectiveness of antimalarial drugs, in particular the emergence of artemisinin resistance, are forcing malaria experts to consider revising the definitions of drug resistance for Plasmodium falciparum.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
